Login Register
English
0

Cart

$ 0

JAK2/3 (Phospho-Tyr966/939) Polyclonal Antibody

JAK2/3 (Phospho-Tyr966/939) Polyclonal Antibody

Views(4) Publications(0) Catalog no(ABP58985)
Datasheet Print Share Email Share
  • Specification
  • FAQ
  • Publications(0)
  • Comments(0)

Specification

Product name JAK2/3 (Phospho-Tyr966/939) Polyclonal Antibody
Immunogen Synthesized peptide derived from part region of human JAK2/3 (Phospho-Tyr966/939) Antibody protein at amino acid sequence of T966
Host Rabbit
Reactivity Human:Y966/939,Mouse:Y966/935,Rat:Y966/935
Applications WB,ELISA,IHC
Applications notes Optimal working dilutions should be determined experimentally by the investigator. Suggested starting dilutions are as follows: WB 1:500-2000;IHC 1:50-300;ELISA 1:2000-20000
Clonality Polyclonal
Preparation method The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Alternative Tyrosine-protein kinase JAK2/JAK3; Janus kinase 2/Janus kinase 3; JAK-2/JAK-3

Product Properties

Formulation Liquid solution
Concentration 1 mg/ml
Storage buffer Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Storage instructions Stable for one year at -20°C from date of shipment. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Aliquot to avoid repeated freezing and thawing.
Shipping Gel pack with blue ice.
Precautions The product listed herein is for research use only and is not intended for use in human or clinical diagnosis. Suggested applications of our products are not recommendations to use our products in violation of any patent or as a license. We cannot be responsible for patent infringements or other violations that may occur with the use of this product.

Additional Information

Background JAK2 is a kinase that is misregulated or mutated in a number of myeloproliferative diseases and cancers. The mutation V617F is the most clinically relevant variant, and is seen in around half of myeloproliferative disorders. The variant is a known activating mutation, and activated JAK2 is sufficient to drive myeloproliferative disorders in mouse models. V617F, while most recurrent, is not the only mechanism by which JAK2 can be activated in patients. JAK2 is now one of the first diagnostic markers tested upon diagnosis with a myeloproliferative disorder.
Gene ID 1132/1124
Alternative Tyrosine-protein kinase JAK2/JAK3; Janus kinase 2/Janus kinase 3; JAK-2/JAK-3
Others The antibody detects endogenous levels of JAK2/3 when Phospho occurs at Tyr966/939(human) or Tyr966/935(mouse/rat) , It doesn't react with total protein.
Accession O60674/P52333

Image & description

Fig.1. Western Blot analysis of 1, Mouse-liver 2, hela 3,Mouse-brain cells using primary antibody diluted at 1:1000 (4°C overnight). Goat Anti-rabbit IgG Dylight 800 (Cat #: A23920) secondary antibody was diluted at 1:5000 at 25°C for 1 hour.

Fig.1. Western Blot analysis of 1, Mouse-liver 2, hela 3,Mouse-brain cells using primary antibody diluted at 1:1000 (4°C overnight). Goat Anti-rabbit IgG Dylight 800 (Cat #: A23920) secondary antibody was diluted at 1:5000 at 25°C for 1 hour.

Fig.2. Western Blot analysis of hela cells using primary antibody diluted at 1:1000 (4°C overnight). Goat Anti-rabbit IgG Dylight 800 (Cat #: A23920) secondary antibody was diluted at 1:5000 at 25°C for 1 hour.

Fig.2. Western Blot analysis of hela cells using primary antibody diluted at 1:1000 (4°C overnight). Goat Anti-rabbit IgG Dylight 800 (Cat #: A23920) secondary antibody was diluted at 1:5000 at 25°C for 1 hour.

This product has been cited in0publications

Reviews

There are no reviews yet.

Be the first to review “JAK2/3 (Phospho-Tyr966/939) Polyclonal Antibody”